NLNathalia De León-Fernández

Nathalia De León-Fernández

*This is an algorithmically generated author record based on publicly available information.

Nathalia De León-Fernández has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Persistencia de acalasia en presencia de hernia hiatal y vólvulo gástrico. Un reto quirúrgico

    by Nathalia De León-Fernández, Rafael Eduardo Arraut-Gamez, Felipe Anduquia-Garay, Bernardo Borráez-Segura

    La asociación de acalasia y hernia hiatal (HH) tiene prevalencias variables (4-20 %) y su diagnóstico es un reto dada la presencia de síntomas semejantes 1,2. La identificación oportuna de la acalasia permite realizar una miotomía de Heller con funduplicatura, además de la corrección de la HH en el mismo tiempo quirúrgico 1,2. Pese a un adecuado tratamiento, un grupo reducido de pacientes puede presentar persistencia o recaída de la acalasia con HH y requerir una nueva cirugía, que se recomienda se direccione a centros de referencia de enfermedades esofágicas con amplia experiencia 3-5.

  • Pediatric Pleomorphic Adenoma of the Palate

    by Nathalia De León-Fernández, Brandon Galviz Tabares, Silvia V. Agudelo Mendoza, Ilse G. García Rodríguez, Adonis Tupac Ramirez-Cuéllar

    Pleomorphic adenoma (PA) is the most common benign salivary gland tumor and can also arise in minor salivary glands, particularly in the palate. Although generally benign, PA carries a risk of recurrence and malignant transformation, emphasizing the importance of accurate diagnosis. We report the case of a 16-year-old male with a 2-year history of an asymptomatic palatal mass. Initial open biopsy was performed, followed by magnetic resonance imaging, which revealed a subepithelial mass without invasion of surrounding structures. Complete surgical excision with local flap reconstruction was achieved, complicated by wound dehiscence that required revision. Final histopathology confirmed PA, and the patient remains disease-free after 2 years of follow-up. This case highlights the diagnostic and therapeutic challenges of minor salivary gland tumors in pediatric patients, particularly the limitations of open biopsy and fine-needle aspiration. Evidence from recent studies suggests that core needle biopsy provides higher diagnostic accuracy with fewer complications and may represent a safer, less invasive alternative. Further prospective studies are needed to validate core needle biopsy as the standard diagnostic tool for minor salivary gland tumors.


  • Open Access

    Efficacy and Safety of Oral Spironolactone for Women With Acne Vulgaris: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials With Trial Sequential Analysis

    by Laura Ghanem, Najwaa Kirmani, Nathalia De León Fernández, María Paula Palacios‐Ortiz, Juan David Rodríguez‐Parra, Corina A. Rusu

    Background: Adult acne vulgaris is a chronic inflammatory skin condition that primarily affects females. Initial management includes topical and oral medications, but important limitations include ineffectiveness, nonadherence, and adverse effects. Spironolactone has shown good results in off‐label acne management.Aims: We aim to conduct a systematic review and meta‐analysis exploring the safety and efficacy of oral spironolactone for females with acne.Methods: We searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) comparing oral spironolactone in women with acne to placebo. The primary endpoint was the objective assessment of acne improvement. Secondary endpoints included subjective assessment and adverse events. Statistical analysis was performed using Review Manager 5.4. Heterogeneity was assessed with I2 statistics.Results: We included 563 patients from 5 RCTs, of which 251 (42.9%) received spironolactone. Objective assessment of acne improvement (OR 6.59; 95% 3.50–12.43; p < 0.00001; I2 = 0%) was sixfold higher in the spironolactone group compared with placebo. Subjective assessment showed no difference between the two groups (OR 5.22; 95% 0.62–44.24; p < 0.13; I2 = 85%). Menstrual irregularities (OR 1.09; 95% 0.37–3.25; p = 0.88; I2 = 33%) and breast enlargement (OR 1.37; 95% 0.79–2.38; p = 0.26; I2 = 0%) were nonsignificant in patients taking spironolactone. Trial sequential analysis (TSA) confirmed that the required sample size was reached, favoring spironolactone over placebo.Conclusion: Our study suggests that oral spironolactone improves acne in female patients compared to placebo without increasing risks; thus, it should be elevated from “off‐label” use to an officially recommended standard of care.PROSPERO Registration: CRD42024626984.